Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs United States Brent Oil Fund LP (BNO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs United States Brent Oil Fund LP — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while United States Brent Oil Fund LP trades at $43.58. The key difference: United States Brent Oil Fund LP is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BNO | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Commodities - Energy |
52-Week High | $491.22 | $60.13 |
52-Week Low | $278.09 | $27.20 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BNO trades at $42.15, showing minimal daily movement with a slight 0.05% decline. Technical indicators present a neutral to bearish picture with mixed signals from moving averages and oscillators. Recent news highlights oil price volatility driven by Middle East tensions, with WTI crude experiencing significant swings. The stock currently trades near its pivot point of $42, with immediate support at $42 and resistance at $43.
The outlook remains cautious as geopolitical risks and oil market volatility create uncertainty. While strategic oil reserve buying through 2028 may provide demand support, concerns about China's oil demand recovery and potential market surpluses present headwinds. The neutral technical stance suggests waiting for clearer directional momentum before establishing significant positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →
